Skip to content

Zymeworks ZYME Stock issued for employee stock purchase plan

Stock issued for employee stock purchase plan at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.11M-8.5%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's stock issued for employee stock purchase plan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's stock issued for employee stock purchase plan?
Zymeworks (ZYME) reported stock issued for employee stock purchase plan of $649K in Q1 2026.
How has Zymeworks's stock issued for employee stock purchase plan changed year-over-year?
Zymeworks's stock issued for employee stock purchase plan decreased by 10.4% year-over-year, from $724K to $649K.
What does stock issued for employee stock purchase plan mean?
The value of common stock issued to employees through an Employee Stock Purchase Plan (ESPP). This reflects the level of employee participation in equity ownership and serves as a component of the company's overall compensation and capital structure strategy.